US biopharma company Vivus (Nasdaq: VVUS) saw its shares plunge 24% to $11.38, after reporting third-quarter 2012 financial results, showing that its recently launched weight management drug Qsymia (phentermine and topiramate extended-release) delivered weak sales of just $41,000 in the final month, after a September 17 launch, compared with analysts’ average expectations of about $310,000, according to Thomson Reuters.
Qsymia, along with Arena Pharmaceuticals’ Belviq (lorcaserin, which has yet to come to market as it awaits classification from the Drug Enforcement Agency), became the first new diet pills to receive marketing approval from the US Food and Drug Administration in around 13 years.
For the third quarter, Vivus recognized net product revenues of $41,000 from prescriptions shipped from certified pharmacies to patients. Given the lack of history in selling Qsymia, the company will recognize revenue on the sell-through method, that is, revenue is recognized as prescriptions are shipped to patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze